By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


GANYMED Pharmaceuticals AG 

Freiligrathstrasse 12

Mainz    D-55131  Germany
Phone: 49-0-6131-1440-10 Fax: 49-0-6131-1440-111




Company News
ASCO2016: GANYMED Pharmaceuticals AG's IMAB362 Extends Survival In Gastric Cancer 6/6/2016 12:39:09 PM
GANYMED Pharmaceuticals AG To Present Exciting Phase II Clinical Data For IMAB362 In Gastroesophageal Cancer At ASCO 2016 Annual Meeting 5/17/2016 10:32:05 AM
BioNTech AG GANYMED Pharmaceuticals AG Open New Research Headquarters In Mainz, Germany 10/1/2014 9:59:25 AM
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014 9:41:23 AM
GANYMED Pharmaceuticals AG's IMAB362 Shows Strong Evidence Of Single-Agent Activity In Phase 2a Trial In Gastroesophageal Cancer 5/27/2014 11:39:08 AM
GANYMED Pharmaceuticals AG's IMAB027 Enters Phase I/II Clinical Trial For Ovarian Cancer 2/12/2014 8:59:37 AM
GANYMED Pharmaceuticals AG To Present At The 32nd Annual J.P. Morgan Healthcare Conference 12/19/2013 9:35:30 AM
GANYMED Pharmaceuticals AG Scrounges Up $60 Million Financing Round 11/18/2013 8:59:58 AM
GANYMED Pharmaceuticals AG's IMAB362 Receives Orphan Drug Designation From FDA and European Medicines Agency for Pancreatic Cancer 10/21/2013 8:58:29 AM
GANYMED Pharmaceuticals AG Announces CE Marking for Test to Assess Claudin-18.2 Expression in Solid Tumors 9/11/2013 8:17:50 AM